company news
2019.05.05 size

on may 5, 2019, hansoh’s fulaimei® (polyethylene glycol loxenatide for injection) (available in 0.5ml:0.1mg and 0.5ml:0.2mg) received nda approval from national medical products administration.

polyethylene glycol loxenatide is a glp-1 receptor agonist. it is a category 1.1 innovative drug, independently developed by hansoh based on long-acting drug proprietary technology, for the treatment of type 2 diabetes. as a result of its molecular structure, polyethylene glycol loxenatide only needs one injection per week to achieve a long-term effect.